To further explore innovative development paths for the private economy, Lu Jianxin, Vice Chairman of the Nantong Municipal Committee of the Chinese People's Political Consultative Conference and Chairman of the Nantong Federation of Industry and Commerce, led a team to Chongchuan on the afternoon of August 20th for a special research trip. Lu Zhixiang, member of the Party Leadership Group and Vice Chairman of the Nantong Federation of Industry and Commerce; Zhang Mingxing, member of the Standing Committee of the Chongchuan District Party Committee, Director of the United Front Work Department and Director of the Organization Department; Su Meiyun, Vice Chairman of the Chongchuan District Committee of the Chinese People's Political Consultative Conference and Chairman of the District Federation of Industry and Commerce; Zhu Yan, Director of the Office (Research Office) of the Nantong Federation of Industry and Commerce; and Zhang Wei, Deputy Director of the Chongchuan District United Front Work Department and Secretary of the Party Leadership Group of the District Federation of Industry and Commerce, accompanied the delegation.
Lu Jianxin and his delegation visited Nantong Enove Precision Plastic Catheter Co., Ltd. and other companies, went deep into the R&D and production lines of the companies, had face-to-face exchanges with the company leaders, learned in detail about the company's operating model, product structure, production and operation, and fully exchanged the company's practices in the R&D and innovation process.
Qin Xiaopeng, general manager of Nantong Enove Precision Plastics Catheters, introduced to Lu Jianxin and his party that as a private technology-based enterprise in the medical catheter industry, Enove insists on R&D and innovation, benchmarks against international cutting-edge technologies, and combines multiple business models such as OEM, ODM, CDMO, and MAH. In the fierce domestic and international competition, Enove has taken the initiative and expanded its position by relying on its independent core technology and lean manufacturing capabilities.
By early of year of 2025, the new 18,000-square-meter facility, with a total construction area of 38,000 square meters, was fully operational, completely overcoming the bottleneck previously limiting production capacity. Meanwhile, Enove has increased investment in high-tech talent and production R&D equipment. This unleashing of the company's potential has attracted the attention of numerous domestic and international medical device companies. From February to June of this year, several internationally renowned leading medical device companies conducted on-site audits of Enove and received immediate approval, leading to partnership agreements and creating new opportunities for high-quality development.
Lu Jianxin fully recognized Enove’s achievements in technological innovation and business management. He emphasized that private enterprises should further deepen reforms, enhance their core competitiveness, and promote high-quality development through product and model innovation. They should increase R&D investment, optimize corporate management, strengthen talent training, and improve operational efficiency. He also stated that the municipal and district Federations of Industry and Commerce will continue to support the development of private enterprises, actively building platforms and providing services to create a favorable environment for their development.
